Chargement en cours...
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors
The therapeutic landscape of chronic lymphocytic leukemia (CLL) underwent a paradigm shift in 2014 with the approval of ibrutinib, which binds covalently to the C481 residue of Bruton’s tyrosine kinase (BTK) and irreversibly inhibits it. A number of large, phase 3 trials conducted in both the frontl...
Enregistré dans:
| Publié dans: | Fac Rev |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Faculty Opinions Ltd
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7946394/ https://ncbi.nlm.nih.gov/pubmed/33718939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12703/r/10-22 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|